BOSTON, May 12, 2023
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq:
NRBO), a clinical-stage biotechnology company on a quest to
transform cardiometabolic diseases, today announced the appointment
of Mark A. Glickman to its Board of
Directors, effective as of May 11,
2023.
"Mark is a highly accomplished pharmaceutical industry executive
with more than 30 years of industry experience, including many
senior leadership positions," said Andrew
I. Koven, Chairman of NeuroBo's Board of Directors. "I am
pleased to welcome Mark to the NeuroBo Board of Directors and look
forward to his contributions as we pursue the clinical development
of our two cardiometabolic assets; DA-1241, a novel
G-Protein-Coupled Receptor 119 (GPR119) agonist for which we plan
to initiate a two-part, Phase 2a clinical trial for the treatment
of nonalcoholic steatohepatitis (NASH) in the third quarter of
2023. Our second asset, DA-1726, is a novel oxyntomodulin
(OXM) analogue that acts as a glucagon-like peptide-1 receptor
(GLP1R) and glucagon receptor (GCGR) dual agonist, which we expect
to bring through the Investigational New Drug (IND) application
process, with the goal of initiating a Phase 1a safety study in the
first half of 2024."
"I am excited to join the NeuroBo Board of Directors at such an
important stage for the Company, especially during the advancement
of the Company's two promising cardiometabolic assets," said Mr.
Glickman. "I look forward to working with my fellow Directors and
the NeuroBo leadership team as we position the Company for
long-term growth and value creation."
Mr. Glickman has over 30 years of experience in the
pharmaceutical and medical device industry, where he began his life
sciences career as a diagnostic sales representative and progressed
in roles of increasing responsibility to senior executive
positions. Mr. Glickman was most recently the Co-Chief Executive
officer for TherapeuticsMD, Inc. from 2022 through the sale of the
company's assets to Mayne Therapeutics in January 2023. Prior to this role, he served as
Chief Business Officer, Commercial of TherapeuticsMD, Inc. since
June 2021. Previously, from
April 2018 until December 2020, Mr. Glickman was the Chief
Commercial Officer for Esperion Therapeutics, Inc., where he
developed and led the commercial division in the launch of the
company's first cardiovascular prescription therapy. From
June 2015 to March 2018, Mr. Glickman served as the Chief
Commercial Officer for Aralez Pharmaceuticals Inc., where he built
out and led the first commercial effort for a previously clinical
organization. Prior to this, he was Executive Vice President of
Sales and Marketing for Auxilium Pharmaceuticals (Endo
Pharmaceuticals), during which time, he led all commercial efforts
for a portfolio of 13 pharmaceutical products. Mr. Glickman's
previous positions include Senior Vice President of Sales and
Marketing and Vice President of Medical Devices for Otsuka America
Pharmaceuticals Inc., and marketing head, Regional Sales Director
and Vice President of Sales and Operations at Kos Pharmaceuticals
(a subsidiary of Abbott Laboratories), where he expanded his skills
in the commercial products area.
Mr. Glickman received a Bachelor of Arts in Political
Science from the State University of New York
Oswego, and a Master of Business Administration in Finance
and International Management from New York
University's Stern School of Business.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc., is a clinical-stage biotechnology
company on a quest to transform cardiometabolic diseases. The
company is currently developing DA-1241 for the treatment of
Non-Alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus
(T2DM), and is developing DA-1726 for the treatment of obesity.
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist,
which promotes the release of key gut peptides GLP-1, GIP, and PYY.
In preclinical studies, DA-1241 demonstrated positive effect on
liver inflammation, lipid metabolism, weight loss, and glucose
metabolism, reducing hepatic steatosis, hepatic inflammation, and
liver fibrosis, while also improving glucose control. DA-1726 is a
novel oxyntomodulin (OXM) analogue that acts as a glucagon-like
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual
agonist. OXM is a naturally-occurring gut hormone that activates
GLP1R and GCGR, thereby decreasing food intake while increasing
energy expenditure, thus potentially resulting in superior body
weight loss compared to selective GLP1R agonists.
For more information, please
visit www.neurobopharma.com.
Forward Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements about the closing of the offering of
securities. Forward-looking statements are predictions, projections
and other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated with
our ability to execute on our commercial strategy, the timeline for
regulatory submissions, regulatory steps and potential regulatory
approval of our current and future product candidates, the ability
to realize the benefits of the license agreement with Dong-A ST Co.
Ltd., including the impact on future financial and operating
results of NeuroBo; the ability to integrate the new product
candidates into NeuroBo's business in a timely and cost-efficient
manner; the cooperation of our contract manufacturers, clinical
study partners and others involved in the development of our
current and future product candidates; our ability to initiate and
complete clinical trials on a timely basis; our ability to recruit
subjects for our clinical trials; costs related to the license
agreement, known and unknown, including costs of any litigation or
regulatory actions relating to the license agreement; changes in
applicable laws or regulations; effects of changes to NeuroBo's
stock price on the terms of the license agreement and any future
fundraising; and other risks and uncertainties described in our
filings with the SEC. Forward-looking statements speak only as of
the date when made. NeuroBo does not assume any obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Contact:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-inc-appoints-pharmaceutical-industry-executive-mark-a-glickman-to-its-board-of-directors-301823219.html
SOURCE NeuroBo Pharmaceuticals, Inc.